RankingsPricing
  1. US-listed companies
  2. Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc.HEPA

Market cap
$2.94M
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Jun 30,
2014		Jun 30,
2015		Jun 30,
2016		Jun 30,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022
Net loss--14,347,877-16,998,638-14,891,050-9,449,295-6,718,698-20,353,938-32,722,168-42,200,049
Stock-based compensation195,2262901,8672234,51066,176253
Depreciation and amortization1,32116,35521,52527,99318,78726,73734,515077,461
Change in fair value of contingent consideration----265,398-160,000140,0002-414,992
Impairment of goodwill--------2
Accounts payable and accrued expenses--3-2,128,263-897,695-424,3573-1,067,8472
Right of use asset--------252,803-253,104
Operating lease liability--------258,589-263,378
Prepaid expenses and other assets168,621563,974-191,973-287,64482,021330,24714-917,308
Net cash used in operating activities----19,172,110-15,646,027-7,565,059-16,165,202-31-35
Purchase of property and equipment15,84783,2696,60314,709-51,46987,983130,40516,336
Proceeds from disposal of property and equipment----900-2,194-2,266
Net cash used in investing activities----14,709900-51,469-85,789-130,405-14,070
Proceeds from Issuance of Common Stock---25284382-
Proceeds from Issuance of Convertible Preferred Stock-13--10---18
Redemption of Series F and Series G Convertible Redeemable Preferred Stock--------21
Repayment of debt financing-------176,585-
Contingent consideration milestone payment----1,000,000---2
Net cash (used in) provided by financing activities---2513194382-5,137,500
Effect of exchange rates on cash---------47,138
Net (decrease) increase in cash-----112751-40,159,879
Cash paid for interest-------2,024941
Conversion of Stock, Amount Converted-------11,0005,000
Stock Issued-----500,244--5,008
Fair value of warrants issued to placement agent-------2-
Adoption of new accounting standard-------11,672-